Natural Biocon (India) Ltd

Natural Biocon has shown significant growth in net sales from zero in Mar'20 to 8.35 Cr in Mar'25, peaking at 13.53 Cr in Mar'24, but has faced declining operating profit and profit after tax in recent years. Total assets increased to 38.52 Cr by Mar'25, driven by substantial investments, while cash flow from operations turned positive at 1.00 Cr.

Natural Biocon will announce its results on 12 November 2025.

As of N/A, Natural Biocon (India) Ltd's stock price is 7.11, down 4.95%, with significant declines over various time frames, including a year-to-date drop of 45.35%. This underperformance contrasts with the Sensex's gains, highlighting the stock's struggles in a generally positive market.

Natural Biocon's historical performance shows significant sales growth from zero in Mar'20 to 8.35 Cr in Mar'25, despite a decline from 13.53 Cr in Mar'24. The company faces challenges with profitability and cash flow, as profits and earnings per share have decreased, and there has been no operational cash generation.

Natural Biocon has experienced fluctuating financial performance, with net sales growing from zero in Mar'20 to 8.35 Cr in Mar'25, but profitability has declined, with profit after tax dropping from 0.18 Cr in Mar'23 to 0.04 Cr in Mar'25. Despite growth in sales and total assets, operating profit and earnings per share have also decreased in recent years.

Natural Biocon will announce its results on 13 August 2025.

As of 24th July, Natural Biocon (India) Ltd has a market capitalization of 31.00 Cr, with recent net sales of 8.36 Cr and a net profit of 0.06 Cr. The company reported shareholder's funds of 12.38 Cr and total assets of 16.77 Cr for the annual period ending March 2024.

Natural Biocon (India) Ltd operates in the chemicals and natural extracts sector within the Pesticides & Agrochemicals industry, reporting net sales of 14 Cr and a net loss of 5 Cr for the quarter ending March 2025, with a market cap of INR 31 Cr. The company has no debt and offers no dividends.

The top shareholders of Natural Biocon include Gitaben Sureshbhai Shah, the largest promoter with 3.3%, and Aventez Media & Technologies Limited, the largest public shareholder with 9.7%. Individual investors collectively hold 33.35% of the shares, with no institutional holdings reported.

Natural Biocon's historical performance shows fluctuating net sales, peaking at 13.53 Cr in Mar'24 before declining to 8.35 Cr in Mar'25, alongside decreasing profitability, with net profit dropping from 0.15 Cr to 0.04 Cr in the same period. Rising operational costs contributed to lower operating profit margins and earnings per share.

As of March 2023, the management team of Natural Biocon includes Arunkumar D Prajapati (Chairman/Executive Director), Manish Patel (Executive Director & CFO), and three Independent Non-Executive Directors: Darshangi Patel, Suryakant Govind Lohar, and Bhaskar Waman Vishe. They oversee the company's operations and strategic direction.

Natural Biocon's peers include P I Industries, UPL, Bayer CropSci., and others, with varying management risks and growth rates. Sharda Cropchem leads in 1-year returns at 102.43%, while Natural Biocon's return is -5.03%, better than Adarsh Plant's -10.98%.

As of 05-Jun, Natural Biocon (India) Ltd is experiencing a price increase to 12.06, up 4.96%. Despite a year-to-date decline of 7.30%, recent gains and increased investor participation indicate a potential recovery and favorable outlook.